LIXTE Biotechnology, a publicly traded company in the U.S., has launched a cryptocurrency reserve strategy, planning to allocate 25% of its funds to BTC
ChainCatcher news, Nasdaq-listed company LIXTE Biotechnology announced that its board has approved a strategic capital allocation plan to acquire cryptocurrency as part of the company's funds. The company's board also approved allocating 25% of the funds to cryptocurrency, including Bitcoin and other potential digital assets (as applicable).
Risk warning Risk warning
Related tags
